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Clinical efficacy of concomitant tibial interventions
associated with superficial femoral artery
interventions in critical limb ischemia
Christopher J. Smolock, MD, Javier E. Anaya-Ayala, MD, Hosam F. El-Sayed, MD,
Joseph J. Naoum, MD, Alan B. Lumsden, MD, and Mark G. Davies, MD, PhD, MBA, Houston, Tex
Background: Combined superficial femoral artery (SFA) and tibial angioplasty (TA) are a common treatment for critical
limb ischemia. Poor tibial runoff significantly compromises durability and clinical effectiveness of SFA interventions. The
aim of this study is to determine clinical and anatomic outcomes of SFA interventions in patients with equally
compromised runoff, with and without concomitant TA.
Methods: The database of patients undergoing endovascular treatment of SFA (1999-2009) was retrospectively queried.
Patients with poor runoff, scored >10 by modified Society for Vascular Surgery criteria, were selected. Preoperative
angiograms were reviewed to assess distal popliteal and tibial runoff. Kaplan-Meier analyses were performed to assess
time-dependent outcomes. Factor analyses were performed for time-dependent variables.
Results: A total of 162 limbs with a runoff score >10 (56% men; average age, 69 years) underwent endovascular
intervention for symptomatic SFA disease: 61 (54% men) underwent TA but the remaining 101 (57% men) did not. The
groups were matched for age, sex, and SFA anatomy (Trans-Atlantic Inter-Society Consensus II C/D lesions: 56% no TA
vs 62% TA; P .5). Presenting symptoms were similar between no TA and TA groups (rest pain: 40% vs 32%; tissue loss:
60% vs 68%; P  .3). Three-year survival favored the TA group (79%  5%) vs no TA (68%  5%; P  .06). Three-year
anatomic outcomes in no TA vs TA group, including primary patency (45% 6% vs 63% 8%; P .04), assisted primary
patency (55%  6% vs 75%  7%; P  .03), and secondary patency (57%  6% vs 77%  7%; P  .03) were all superior in
the TA group. Target vessel revascularization in no TA vs TA (61%  6% vs 74%  8%; P  .002) and target extremity
revascularization (42% 6% vs 59% 8%; P .06) also favored the TA group. However the comparison of no TA vs TA
for clinical success (39% 6% vs 47% 8%; P  .6), freedom from recurrent symptoms (59% 6%vs 60% 9%; P  .1),
amputation-free survival (46%  5% vs 63%  7%; P  .06), and limb salvage at 3 years (63%  6% vs 74%  7%; P  .6)
were similar.
Conclusions: TA in patients with poor runoff has a positive effect on SFA anatomic outcomes. However, clinical success
was not affected. Concomitant TA appears not to add clinical benefit to SFA intervention in critical limb ischemia.
(J Vasc Surg 2013;57:19-27.)
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remains a significant problem for vascular surgeons and is
associated with significant perioperative morbidity and
mortality. There has been a greater emphasis placed on
aggressive endoluminal therapy for superficial femoral ar-
tery (SFA) and tibial lesions before consideration of bypass
surgery because these interventions are associated with
reduced perioperative mortality and morbidity and equal
short-term efficacy.1-3 Interventions for SFA occlusive dis-
ease are now commonplace and 50% are performed for
critical limb ischemia.4 We have demonstrated that poor
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http://dx.doi.org/10.1016/j.jvs.2012.06.110ibial vessel runoff impacts the long-term outcomes of SFA
ndoluminal interventions in patients with rest pain and
issue loss.5,6 The impact of tibial interventions, which
hould improve tibial runoff and thus improve the outcome
f SFA interventions, has not been extensively examined.
he aim of this study is to determine the clinical and
natomic outcomes of SFA interventions in patients suffer-
ng from critical limb ischemia with equally compromised
unoff, with and without concomitant tibial interventions.
ETHODS
Study design. A database of patients undergoing en-
ovascular treatment of SFA arteries between 1999 and
009 was retrospectively queried. Patients with Rutherford
ymptom classification 4, 5, and 6 were selected. Angio-
rams were reviewed in all cases to assess distal popliteal and
ibial runoff. Preprocedure runoff was scored according to
modification of the Society for Vascular Surgery (SVS)
riteria such that a higher score implies worse runoff (max-
mum 19). Only patients with poor runoff defined by a
unoff score 10 were selected. Our use of the data was
nder the category of secondary use of pre-existing data as
efined by the Institutional Review Board and the Health
nsurance Portability and Accountability Act.
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medical center with 1000 beds in a catchment area of 5
million people. It is a tertiary and quaternary referral
facility.
Methodology. For each patient captured, demo-
graphics, symptoms, existing comorbid conditions, and risk
factors for atherosclerosis were identified. For each patient,
risk factors were identified and corrected through their
primary care providers. Therapy for individual patients was
dictated by individual attending physician preference and
was not regulated by unit guidelines. Patients were prefer-
entially offered endoluminal intervention, if appropriate,
before referral for bypass surgery. All patients received
aspirin daily (81 mg or 325 mg) preoperatively as a general
cardiovascular protection agent. In the last 3 years, all
patients received perioperative statin therapy. In the last 5
years, patients also received clopidogrel preoperatively.
Patients with serious symptoms or signs of severe ste-
nosis/occlusion based on the initial noninvasive tests re-
ceived angiograms. Angiograms and angiographic reports
were reviewed. SFA and tibial lesions were categorized
under the Trans-Atlantic Inter-Society Consensus (TASC-
I/II) system.7,8 The preoperative distal runoff was scored
by vessel resistance and according to a modification of SVS
criteria used for determining bypass runoff using the cumu-
lative score for the distal popliteal (from the knee joint to
first tibial branch; maximum, 9  1) and each of the tibial
vessels (maximum, 3 each), giving a maximum possible
total score of 19, with a higher score indicating a worse
score.5
Angioplasty was performed under systemic heparin ad-
ministration (40-60 U/kg), and completion angiography
was performed to assess the technical result. Stents were
used (at the discretion of the operator) primarily or as an
adjunct for flow-limiting dissections, intimal flaps, or poor
technical results (50% residual stenosis). No covered
stents were used. No procedures or interventions were
performed that could have potentially jeopardized the out-
flow vessel for a bypass. The complexity of each interven-
tion was scored according to the ad hoc system described by
DeRubertis et al9 in which 1 point was awarded for an
intervention in the iliac, femoral or tibial segments of the
leg.
Patients who had a successful endoluminal intervention
received 75 mg of clopidogrel. While a patient was taking
clopidogrel, aspirin (81 mg) and statin therapy was main-
tained. Patients taking clopidogrel before the intervention
remained on clopidogrel after the intervention. Clopi-
dogrel therapy was continued for 30 days after interven-
tion.
Patients underwent routine duplex follow-up at 1, 3,
and every 6 months after their procedure using criteria
previously described.5 During follow-up, angiography was
only performed if noninvasive studies suggested resteno-
sis/occlusion (positive duplex scan with a drop in the
ankle-brachial index [ABI] of0.15 and toe-brachial index
of 0.1) and the patient had recurrent symptoms. aDefinitions. Coronary artery disease was defined as a
istory of angina pectoris, myocardial infarction, conges-
ive heart disease, or prior coronary artery revasculariza-
ions. Cerebrovascular disease was defined as a history of
troke, transient ischemic attack, or carotid artery revascular-
zation.Chronic renal impairmentwas defined as an estimated
lomerular filtration rate 60 mL/min/1.73 m2 or a pa-
ient on dialysis. Hypertension was defined as a systolic
lood pressure 150 mm Hg or diastolic blood pressure
90 mm Hg on three occasions during a 6-month period.
ypercholesterolemia was defined as fasting serum concen-
rations of cholesterol 200 mg/dL, a low-density lipo-
rotein 130 mg/dL, or triglycerides 200 mg/dL.
Diabetes was defined as a fasting plasma glucose 110
g/dL or an HbA1c7%. Noninsulin-dependent diabetes
ellitus was defined as any patient with diabetes mellitus
ho did not routinely receive insulin therapy for their
iabetes management. Insulin-dependent diabetes mellitus
as defined as any patient with diabetes mellitus who
outinely received insulin therapy.Metabolic syndrome was
efined as the presence of more than three of the following
riteria: blood pressure 130/85 mm Hg; triglycerides
150 mg/dL; high-density lipoprotein 50 mg/dL for
omen and 40 mg/dL for men; fasting blood glucose
110 mg/dL; or body mass index 30 kg/m2.10
ASC-II classification of disease severity for femoral lesions
as used to define the categories of lesions.7
A death 30 days of the procedure was considered
rocedure-related. A major complication was any event,
egardless of how minimal, not routinely observed after
ndoluminal therapy that required treatment with a thera-
eutic intervention or repeat hospitalization 30 days of
he procedure. Systemic complications were those related
o cardiac, pulmonary, or renal symptoms as well as sepsis.
ocal complications were those related to access site, sur-
ical wounds, and the treated limb. A major adverse car-
iovascular event was defined as a myocardial infarction,
troke, or death (any cause). Preprocedural and postproce-
ural symptoms were defined by SVS criteria11 and a drop
n symptom score of 1 or more in follow-up was considered
o be recurrent symptoms. A major adverse limb event was
efined as an above-ankle amputation of the index limb or
ajor repeat intervention (new bypass graft, jump or inter-
osition graft revision, or thrombectomy or thrombolysis).
Primary, assisted primary and secondary patency rates
ere defined in accordance with the SVS reporting stan-
ards. Amputation-free survival was defined as freedom
rom above-ankle amputation of the index limb or death.
hort-term clinical efficacy was achieved if all of the follow-
ng occurred: absence of recurrent symptoms for 1 year,
atency of the intervention until wound healing, limb
alvage for 1 year, maintenance of ambulation for 1 year,
nd survival for 1 year. Retained clinical success was defined
s absence of recurrent symptoms, maintenance of ambu-
ation, and limb preservation.
Statistical analysis. All statistical analyses were per-
ormed on an “intention-to-treat” basis. Measured values
re reported as percentages or means standard deviation.
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Meier analyses and reported using current SVS criteria.11
Standard errors are reported in Kaplan-Meier analyses. Cox
proportional hazard analyses and univariate and multivari-
ate analyses were performed to identify factors associated
with outcomes. Analyses were performed using JMP 7.0
software (SAS Institute, Cary, NC).
RESULTS
Patient population. During the study period, 162
limbs underwent endoluminal treatment of the SFA for
critical limb ischemia. Sixty-one limbs (32% rest pain, 68%
tissue loss, 54% men; average age, 71 years) also underwent
tibial angioplasty (TA) of one or more tibial vessels. In the
no-TA cohort, 101 limbs (57% men; average age, 68 years)
presented with rest pain (40%) and tissue loss (60%). Pre-
senting symptoms were similar between groups (rest pain:
40% no TA vs 32% TA; tissue loss: 60% no TA vs 68% TA;
P  .3). Demographics, comorbidities, and preoperative
ambulatory status are reported in Table I. There was no
difference in the comorbidities between the groups except
with regard to smoking history, which was more prevalent
in the TA group. Modified SVS runoff scores were similar
Table I. Characteristics of patients
Variablea No TA TA P
Demographics
Patients, No. 94 56 . . .
Limbs treated, No. 101 61 . . .
Male sex, % 60 54 .5
Age, years 68  17 71  11 .1
Symptoms
Rest pain, % 40 32 .3
Tissue loss, % 60 68
Comorbidities
Smoking history 77 81 .02
Current smoker 13 10 1
Modified cardiac risk index 3.4  1.8 3.4  1.6 1
Coronary artery disease 61 64 .9
Hypertension 89 97 .1
Diabetes 72 74 9
Hyperlipidemia 68 70 1
Statin 63 67 .1
Metabolic syndrome 50 65 .1
Cerebrovascular disease 24 26 .9
Chronic kidney disease 40 32 .4
Hemodialysis 18 15 1
Hypothyroidism 13 20 .2
Hypercoagulability 4 5 1
Preoperative living status
Independent 98 90 .8
Dependent 2 10
Preoperative ambulatory status
Ambulatory 61 58 .5
Ambulatory/homebound 32 33
Nonambulatory/homebound 3 5
Nonambulatory/transfer 4 3
TA, Tibial angioplasty.
aContinuous data are shown with the mean  standard deviation; categoric
data are shown as number unless indicated otherwise.between groups (13.1  1.9 no TA vs 13.0  1.7 TA; sable II). Tibial vessel runoff was also similar between
roups (1.04 0.5 no TA vs 1.02 0.3 TA; P .73). SFA
essel TASC-II lesion categories were evenly distributed
etween groups. However, tibial vessel TASC-II lesion
ategories were skewed toward more severe lesions in the
roup treated with TA. By Cox proportional analysis, fac-
ors that contributed to decreased survival were the pres-
nce of end-stage renal disease on dialysis (relative risk [RR],
.09; 95% confidence interval [CI] 2.29-7.44; P  .001),
yperlipidemia (RR, 2.21; 95%CI, 1.25-4.06;P .001), and
iabetes (RR, 2.14; 95%CI, 1.15-4.24;P .01).Multivariate
nalysis showed statin therapy had a positive impact on sur-
ival (odds ratio, 0.49; 95% CI, 0.34-0.71; P  .001).
Immediate outcomes. Immediate technical success
as achieved in 98% of cases in the SFA in the no-TA
ohort and in 95% of cases in the TA cohort. Aortoiliac
djunctive interventions were similar between groups (5%
o TA vs 4% TA; P  .71; Table III). An expected differ-
nce in procedural complexity score was seen toward TA
1.1 0.4 no TA vs 2.2 0.4 TA; P .0001). An increase
n ABI 0.15% was achieved in 67% of the no–TA-treated
roup but in 83% of the TA group (P  .0001; Table IV).
owever, there was no statistical difference between
roups in average change/increase in ABI. Both groups
ad no statistical difference in immediate postprocedure
able II. Lesion and vessel characteristics
ariablea No TA TA P
ASC-II category, %
Superficial femoral artery
A/B 44 38 .5
C/D 56 62
Tibial
A/B 88 65 .0006
C/D 12 35
unoff
Tibial vessels, No. 1.04  0.49 1.02  0.33 .7
Modified SVS runoff score 13.1  1.9 13.0  1.7 .8
VS, Society for Vascular Surgery; TA, tibial angioplasty; TASC, Trans-
tlantic Inter-Society Consensus.
Continuous data are shown as the mean standard deviation and categoric
ata as indicated.
able III. Procedures and procedural complexity
ariablea No TA TA P
FA intervention, %
Recanalization 39 50 .05
Angioplasty 59 76
Primary stenting 24 14 .3
Atherectomy 4 15
tent usage 29 30 .5
ortoiliac intervention 5 4 .7
omplexity score 1.1  0.4 2.2  0.4 .0001
FA, Superficial femoral artery; TA, tibial angioplasty.
Continuous data are shown as the mean standard deviation and categoric
ata as indicated.ymptoms by International Society for Cardiovascular Sur-
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January 201322 Smolock et algery/SVS grade (3 1), postprocedure ambulatory status,
or discharge status/disposition (Table IV). Although there
was no difference between the groups in postprocedural
ambulatory status, both groups did appear to have an
increase in nonambulatory patients from preprocedural
status. These effects most likely are multifactorial.
Thirty-day outcomes. There were no deaths in either
group 30 days postprocedure (Table V). There was no
difference in overall 30-day morbidity between groups, nor
was there a difference when morbidity was separated into
systemic, local, and lesionmorbidities and compared between
groups, respectively. Regarding objective performance goals,
although there was a trend toward more major adverse limb
events 30 days postprocedure in the no-TA group (25%) vs
TA (15%; P .16), there was no statistical difference between
Table IV. Hemodynamic changes and immediate
symptom relief
Variablea No TA TA P
Hemodynamic changes
Change in ABI 0.22  0.4 0.32  0.4 .1
ABI increase 0.15, % 67 83 .0001
Immediate symptom relief, %
Resolved 2 2 .5
Improved 27 14
No change 53 66
Deterioration 18 19
Post-op ambulatory status, %
Ambulatory 59 70 .5
Ambulatory/homebound 14 8
Nonambulatory/transfer 25 22
Nonambulatory/bedridden 2 0
Discharge status, %
Home 57 68 .5
Rehabilitation facility 19 12
Skilled nursing facility 22 20
Hospital 2 0
ABI, Ankle-brachial index; TA, tibial angioplasty.
aContinuous data are shown as the mean standard deviation and categoric
data as indicated.
Table V. Thirty-day morbidity, mortality, and objective
performance goals
Variable
No TA TA
P(%) (%)
Morbidity and mortality
Mortality 0 0 1
Morbidity 9 10 1
Systemic 2 2 .4
Lesion 3 5 .7
Access site 9 16 .2
Objective performance goals
30-day MACE 2 0 .5
30-day MALE 25 15 .2
30-day major amputation 2 0 .5
MACE, Major adverse cardiovascular event; MALE, major adverse limb
event; TA, tibial angioplasty.groups with respect to 30-day major adverse cardiovascular tvent or 30-day major amputations (above-knee amputations
nd below-knee amputations).
Long-term outcomes. Primary patency (45%  6%
o TA vs 63% 8% TA; P .04), assisted primary patency
55%  6% no TA vs 75%  7% TA; P  .03), secondary
atency (57%  6% no TA vs 77%  7% TA; P  .03),
arget vessel revascularization (51%  6% no TA vs 74% 
% TA; P  .002), and target extremity revascularization
42%  6% no TA vs 59%  8% TA; P  .06) all were
reater in the TA group compared with the no-TA group at
years (Fig 1). However, limb salvage (63% 6% no TA vs
4% 7% TA; P .6), amputation-free survival (46% 5%
o TA vs 63% 7% TA; P .06), freedom from recurrent
ymptoms (59% 6% no TA vs 60% 9% TA; P .1), and
linical success (39% 6% no TA vs 47% 8% TA; P .6)
ll were similar between groups (Fig 2, A-D). Three-year
urvival (68  5% no TA vs 79  5% TA; P  .06) was
uperior in the TA group but did not continue out to 4
ears (Fig 2, E). We did not see a significant difference in
ubsequent bypasses between groups (19% no TA, 14% TA;
 .3). Overall, there was no statistical difference between
he groups with regard to the level of amputation (Table VI).
ISCUSSION
This study reaffirms that SFA interventions and SFA
nterventions combined with tibial vessel interventions in
atients with critical ischemia have a high technical success
ate with a low mortality and morbidity. Both approaches
rovide equivalent measures of immediate symptom relief
nd long-term anatomic outcomes, as measured by patency
ates. However, freedom from recurrent symptoms and
imb salvage, in addition to other metrics such as objective
erformance goals, are not achieved by combining tibial
nterventions with SFA interventions compared with SFA
nterventions alone. Conversely, these measures of patient
ifestyle worsened over 5 years in those patients receiving
ombined SFA and tibial interventions.
An increasing number of patients with multisegment
ower extremity arterial disease as well as more complicated
rterial lesions are currently being treated. Subsequently,
he greater the complexity of the endoluminal case, the
oorer the final outcomes appear to be.9,12 Few studies
ave examined the effect of runoff on the success of endo-
uminal therapy in patients with critical ischemia. It has
een reported that lower procedural event rates and the
ssociated costs are coupled to short-term results that are
omparable to those of bypass surgery. This supports the
ncreasing role of endoluminal therapy for critical ischemia
s a first-line modality.13 But unlike this report, few have
xamined the potential impact of the addition of tibial
rtery endoluminal intervention to SFA intervention in
ritical limb ischemia.
Anatomic criteria to define peripheral vascular runoff
ave been standardized by the 1997 revised SVS/Interna-
ional Society for Cardiovascular Surgery runoff score.11
lthough this score accurately incorporates anastomotic
ite, degree of occlusion, and pedal arch integrity, the use of
his scoring system has not consistently predicted graft
b
e
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Volume 57, Number 1 Smolock et al 23patency, limb salvage, or survival. In addition, the Trans-
Atlantic Inter-Society Consensus for the Management of
Fig 1. Anatomic outcomes: Life-table analysis of patie
patency, (B) assisted primary patency, (C), secondary p
extremity revascularization. Data are the mean standar
in the table. No error bars are shown if the standard error o
at risk is 10. TA, Tibial angioplasty.Peripheral Arterial Disease (TASC) published evidence- oased data concerning treatment of lower extremity periph-
ral arterial disease and treatment recommendations based
ith and without metabolic syndrome for (A) primary
cy, (D), target vessel revascularization, and (E) target
r of the mean, and the number of limbs at risk is shown
mean is10%, and the data set terminates if the numbernts w
aten
d erro
f then presentation and anatomic location of lesions. Origi-
t
i
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January 201324 Smolock et alnally released in January 2000, an updated document was
published in January 2007 (TASC-II).7 In this study, we
Fig 2. Functional outcomes: Life-table analysis of patie
limb salvage, (B) amputation-free survival, (C) freedom
survival. Data are the mean standard error of the mean
No error bars are shown if the standard error of the mean
10. TA, Tibial angioplasty.used immediate and long-term outcomes of endovascular Treatment of similar SFA lesions with or without tibial
nterventions of lesions as categorized by the above system.
ith and without metabolic syndrome are shown for (A)
m recurrent symptoms, (D) clinical success, and (E),
number of patients or limbs at risk is shown in the table.
10%, and the data set terminates if the number at risk isnts w
fro
and
is his allowed us to study and compare the contribution of
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measures of procedural success as well as clinical efficacy (ie,
symptom relief, ambulation, limb salvage, etc).
Patients with critical limb ischemia manifested by rest
pain or tissue loss, or both, are considered higher-risk
surgical candidates. We had low periprocedural morbidity
and no deaths in these groups of patients, and these num-
bers did not differ from reports on endoluminal therapy for
claudication.4 Several other studies have suggested that
endovascular intervention should be considered before
open surgery because it carries a lower periprocedural mor-
bidity and does not compromise limb salvage and subse-
quent vascular intervention compared with bypass sur-
gery.14-17 Historically, lower extremity critical ischemia has
been associated with high death rates over the longer term:
20% to 27% at 1 year,18,19 32% at 2 years,20 and60% at 5
years.21 We found that overall survival in this cohort of
patients was 60% at 5 years (40% mortality). This is likely
linked to a lower initial periprocedural event rate and the
widespread introduction of risk factor reduction measures
in the population.
Multiple studies have shown that the patency rate of
femorotibial and femoroperoneal bypasses is dependent on
the inflow state, the availability of a venous conduit, the
number of calf vessels, the presence of straight flow to the
foot, and the presence of patent pedal vessels.22,23 Biancari
et al24 demonstrated that a better runoff reflected in low
runoff scores will predict hemodynamic success after in-
frainguinal bypass. However, they also demonstrated that
scoring runoff did not allow prediction of immediate or
overall patency. In those patients with a widely patent and
disease-free outflow (runoff score, 1), excellent patency
rates were demonstrated compared with all other runoff
score categories. Several other series have reported sim-
ilar results using the SVS runoff score or modifications
thereof.5,25-27 One of the inquiries in this study is, “Can
runoff and thus outcomes be improved with endoluminal
intervention when it is compromised with concomitant,
multilevel disease?” In addition, “Can these outcomes be
improved despite endoluminal intervention for limb-
threatening ischemia being highly associated with failure
when associated with certain related indicators of lesion
severity and treatment complexity, including increasing
TASC grade, multilevel intervention, tibial intervention,
Table VI. Minor and major amputations
Variable
No TA TA
P(%) (%)
No amputation 58 60 .5
Amputation
Toe and/or forefoot 8 13
Major amputation 34 27
Below knee 22 20 .5
Above knee 12 7
TA, Tibial angioplasty.and reduced tibial outflow?”9 rSeveral previous studies have failed to demonstrate an
verall correlation between angiographic runoff score and
imb salvage.24,26,27 One issue with these studies is they did
ot include substantial numbers of patients with extremely
ompromised outflow (tibial runoff score, 10, using the
tandardized SVS system). Ascer et al28,29 have demon-
trated inferior limb salvage rates with very high hemody-
amic outflow resistance. Others have shown that scores
eflecting blind outflow are a marker for limb loss.5,30
hese data would suggest that limb salvage after endolu-
inal intervention is dependent on runoff. With one excep-
ion,31 most studies addressing the issue of multilevel dis-
ase favor better anatomic outcomes when all levels are
reated with endovascular intervention.32,33
The current study suggests that although runoff in
ultilevel disease is improved by multilevel endovascular
ntervention and is subsequently rendered anatomically
imilar to runoff of SFA disease treated with single-level
ntervention, it is associated with poor long-term limb
alvage and objective performance goals. Furthermore, this
oorer outcome is the case despite the relatively good
urability of multilevel intervention for improved tibial
unoff. When infrainguinal bypasses are required for limb
alvage, it appears that the most common primary causes of
imb loss in the first 30 days are overwhelming progression
f soft-tissue infection despite patent bypass (44%) and
nsufficient runoff in the foot itself (33%).34 Further data
rom Seeger et al35 have demonstrated that amputation is
ignificantly more common in patients with poor runoff
cores (44.4% poor runoff vs 7.4% good runoff; P  .01).
mputation remained significantly more likely to occur in
he tibial intervention group despite the durable improve-
ent of the runoff score by endovascular techniques.
Initial attempts at endoluminal intervention can be
sed in the management of lower extremity ischemia with-
ut compromising limb salvage, patient survival, and sub-
equent vascular intervention, in comparison to bypass
urgery.15 The Bypass Versus Angioplasty in Severe Isch-
mia of the Leg study has demonstrated equivalence when
nfrapopliteal interventions are undertaken.36 But despite
he possibility that tibial interventions may increase outflow
or SFA interventions and thus improve patency and target
essel revascularization, these patients appear to gain no
enefit over patients treated with SFA interventions alone
ith regard to limb salvage, amputation-free survival, free-
om from recurrent symptoms, and clinical success. Per-
aps, the addition of tibial intervention increasing the
omplexity of total endoluminal intervention (ie, SFA 
ibial interventions), accounts for this compromise. Based
n these presented data, we continue to recommend that
A be done concomitant with SFA intervention if anatom-
cally suitable, because TA contributes to patency of the
FA intervention. However, we recommend these inter-
entions exist along a spectrum of therapies that includes
edical therapy and surgical bypass. Until further support-
ng data exist, best judgment of the treating surgeon is
equired.
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January 201326 Smolock et alThere are limitations to the study. The decision to
perform tibial interventions (as well as SFA interventions
along with any adjunct SFA therapies such as stents, ar-
threctomy, etc) was with the treating physician; there was
no group-wide algorithm. In addition to its retrospective
nature, more tibial interventions were performed later in
the experience. However, the early experience was not
devoid of tibial intervention and thus proficiency in the
procedure did exist. Furthermore, the approach to SFA
treatment never changed over time irrespective of treating
the tibial arteries (ie, angioplasty as the therapeutic main-
stay with no difference in primary stenting and atherectomy
of the SFA between groups). Also, improved medical man-
agement and therapies later in the time period should be
considered a variable in the results.
CONCLUSIONS
Tibial intervention in patients with poor runoff has a
positive anatomic effect on primary SFA anatomic out-
comes. However, clinical success, as determined by free-
dom from recurrent symptoms and limb salvage, was no
better after concomitant tibial angioplasty. Concomitant
tibial angioplasty appears not to add significant clinical
benefit to SFA angioplasty in critical limb ischemia.
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